Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendoc...
Ionis Pharmaceuticals, Inc. and Ono Pharmaceutical Co., Ltd (Ono), announced that the two companies have entered into a license agreement in whi...
Nxera Pharma has entered an assignment agreement with Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Pharmaceuticals Ltd (&...
Polycythemia Vera is a rare disorder marked by a continuous rise in the number of red blood cells in the blood, with an accompanying increase in white bloo...
Biogen Inc. and Stoke Therapeutics, Inc. announced a collaboration for the development and commercialization of zorevunersen, a potential f...
Regeneron Pharmaceuticals, Inc.announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® (afliber...
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences com...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomid...
The Global Health Innovative Technology (GHIT) Fund announced a total investment of approximately JPY 2 billion (USD 12.7 million1) in eight...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced it has amended its agreement with Takeda to develop and commercialize osavampator (NB...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai announced results from the Phase 3 LEAP-015 trial evaluating KEYTR...
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for...
Advanced Genomics APAC Co., Ltd. (hereinafter referred to as "Advanced Genomics APAC," headquartered in Taiwan, Managing Director: Andy Chang) is pl...
© 2025 Biopharma Boardroom. All Rights Reserved.
